- Home
- KGEI vs SWKH Comparison
KGEI vs SWKH Comparison
Compare KGEI & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KGEI | SWKH |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Diversified Financial Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.1M | 175.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | KGEI | SWKH |
|---|---|---|
| Price | $4.11 | $17.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 71.3K | 12.6K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.99 | ★ 120.89 |
| EPS | 0.49 | ★ 1.85 |
| Revenue | ★ $60,121,000.00 | $40,149,000.00 |
| Revenue This Year | $6.94 | $52.93 |
| Revenue Next Year | $14.53 | N/A |
| P/E Ratio | ★ $8.31 | $9.26 |
| Revenue Growth | 10.00 | ★ 62.38 |
| 52 Week Low | $3.71 | $13.17 |
| 52 Week High | $9.89 | $20.49 |
Technical Indicators
Market Signals| Indicator | KGEI | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 49.79 | 61.01 |
| Support Level | $3.94 | $16.69 |
| Resistance Level | $4.11 | $17.75 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 89.72 | 66.43 |
Price Performance
Historical ComparisonAbout KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.